CD274 and metastatic melanoma: In a fraction of patients who relapsed after anti-PD-L1 therapy, TILs retained specific anti-tumor cytotoxicity and their infusion resulted in two partial responses in twelve patients with metastatic melanoma, previously relapsed after check-point inhibitors [50].